Mashhad University of Medical Sciences, Mashhad (Iran (Islamic Republic of))
1
presentation
0
follower
6
more
presentations
in this session
Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial
Prevalence, risk factors, and time-trends in abdominal obesity in 36 countries in the WHO African region from 2003 to 2022: a study of 53 WHO STEPS surveys representing 156 million adults